Related by context. Frequent words. (Click for all words.) 80 Patients Undergoing 75 Carotid 74 Heart Failure Patients 73 Ventricular 73 Elderly Patients 73 Meta Analysis 73 Tumor Growth 72 Acute Myocardial Infarction 72 Overactive Bladder 72 Venous Thromboembolism 72 Ischemic 72 Clinical Trial Results 72 Myocardial 72 Thrombolysis 72 Diabetic Patients 71 Stenting 71 Percutaneous Coronary Intervention 71 Blood Flow 71 Esophageal 71 Chronic Heart Failure 71 Resection 71 Cardiovascular Events 71 Pivotal Trial 71 Occlusion 70 Reduces Risk 70 Prostate Cancer Patients 70 Patient Outcomes 70 Gastric Cancer 70 Cardiac Resynchronization Therapy 70 Inhibits 70 Randomized Controlled Trial 70 Post Operative 70 Study Demonstrates 70 Non Invasive 70 Ischemia 70 Prostate Cancer Treatment 70 Postmenopausal Women 70 C Reactive Protein 70 Patients Treated 69 Pulmonary Arterial Hypertension 69 Low Dose 69 Monotherapy 69 Significantly Reduces 69 Metastatic Colorectal Cancer 69 Drug Candidate 69 Blood Clots 69 Hepatic 69 Phase III Clinical Trial 69 Blood Vessel 69 Lung Cancer Patients 69 Drug Eluting Stents 68 Systematic Review 68 Single Dose 68 Completes Enrollment 68 Epithelial 68 Surgical Treatment 68 Urinary Incontinence 68 Phase III Trial 68 Increases Risk 68 Lesion 68 Induces 68 Myocardial Infarction 67 Acute Coronary Syndromes 67 Chronic Hepatitis C 67 Preclinical Data 67 Radiation Exposure 67 Uterine 67 J Am Coll 67 Ultrasonography 67 Prostate Cancer Risk 67 FDA Clears 67 Ablation 67 Aortic 67 Blood Glucose 67 Chronic Lymphocytic Leukemia 67 Targeted Therapy 67 Oxidative Stress 67 Well Tolerated 66 Insulin Resistance 66 Combination Therapy 66 Autoimmune Disease 66 Drug Resistant 66 Patient Enrollment 66 Anticoagulation 66 II Clinical Trial 66 Newly Diagnosed 66 Gum Disease 66 Carcinoma 66 Prognostic 66 Fibrosis 66 Breast Cancer Patients 66 Intraoperative 66 Virtual Colonoscopy 66 Breast Cancer Treatment 66 Blood Vessels 66 Intracellular 66 Hormone Therapy 66 Receives FDA Clearance 66 Enoxaparin 65 Sonography 65 Pivotal Phase III